ESMO Virtual Summit Russia 2021 (10-11 June 2021, Moscow, Russia)

ESMO Virtual Summit Russia 2021

10-11 June 2021


Summit Co-Chairs

  • Karin Jordan, Germany
  • Alexey Tryakin, Russia

Faculty

  • Jean-Pascal Machiels, Belgium
  • Svetlana Kutukova, Russia
  • Ilya Romanov, Russia
  • Pierre Blanchard, France
  • Amanda Psyrri, Greece
  • Elizabeth Smyth, United Kingdom
  • Mark Saunders, United Kingdom
  • Miriam Koopman, Netherlands
  • Ivan Rykov, Russia
  • Karin Jordan, Germany
  • Alexey Tryakin, Russia
  • Mikhail Fedyanin, Russia
  • Alexander Fedenko, Russia
  • Silvia Stacchiotti, Italy
  • Paolo Dei Tos, Italy
  • Robin Jones, United Kingdom
  • Jean-Yves Blay, France
  • Silvie Bonvalot, France
  • Giuseppe Curigliano, Italy
  • Timur Mitin, United States
  • Mona Frolova, Russia
  • Nadia Harbeck, Germany
  • Alexander Petrovsky, Russia

Learning Objectives

  • To provide the oncology community with a summary of the most significant treatment advances presented at the ESMO Congresses
  • To learn how to best sequence or combine therapies in different tumor types
  • To review the current standard of care and emerging therapeutic strategies for key malignancies from a local and international perspective
  • To discuss the current controversies in the management of specific cancers

Accreditation

The programme of this event will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to ESMO-MORA Recertification Process & Requirements.


PROGRAMME

Thursday, June 10th 2021 (Central European Summer Time)

09:50-10:00 – Welcome & Introduction.
Welcome from RUSSCO and ESMO

Karin Jordan, ESMO
Alexey Tryakin, RUSSCO


SESSION 1. Head and Neck Carcinoma

Chairs:
Jean-Pascal Machiels, BE
Ilya Romanov, RU

10:00-10:20 – Advances of 2020-2021 in the locoregional treatment
Jean-Pascal Machiels, BE
10:20-10:25 – Q&A

10:25-10:45 – Advances of 2020-2021 in metastatic disease
Svetlana Kutukova, RU
10:45-10:50 – Q&A

Treatment intensification and de-escalation. Whom and when?

10:50-11:10 – Surgeon`s perspectives
Ilya Romanov, RU

11:10-11:30 – Radiotherapist`s perspectives
Pierre Blanchard, FR

11:30-11:50 – Medical oncologist’ perspectives
Amanda Psyrri, GR

11:50-12:10 – Q&A, panel discussion

12:10-13:10 – Clinical case discussion (3x20’)
Yuri Alymov, RU
Anastasia Ignatova, RU
David Safarow, RU


13:10-14:40 – Virtual Lunch Break

13:30-14:30 – Satellite Symposium MSD


SESSION 2. Colorectal carcinoma

Chairs:
Elizabeth Smyth, UK
Alexey Tryakin, RU

14:40-15:05 – Practice changing studies in rectal carcinoma. Is the total neoadjuvant therapy a new standard of care?
Mark Saunders, UK
15:05-15:10 – Q&A

15:10-15:30 – Practice changing studies in metastatic disease
Miriam Koopman, NL
15:30-15:35 – Q&A

15:35-16:00 – Rectal carcinoma with liver metastases. How to choose the correct route?
Elizabeth Smyth, UK
16:00-16:05 – Q&A

Third line of treatment. Is therapy reinduction a preferred option for the majority of patients?

16:05-16:20 – Pro
Alexey Tryakin, RU

16:20-16:35 – Contra
Ivan Rykov, RU

16:35-16:40 – Q&A

16:40-17:00 – Molecular driven treatment in later lines
Mikhail Fedyanin, RU
17:00-17:05 – Q&A

17:05-18:05 – Clinical case discussion (3x20’)
Elizaveta Poljanskaja, RU
Sergei Kuzin, RU
Michail Kramchaninov, RU


18:05-18:15 – Virtual Break

Hall 1
18:15-19:35 – Bristol Myers Squibb Satellite Symposium

Bristol Myers Squibb Satellite Symposium

Could Immunotherapy Change Our Approaches in the Treatment of Gastric and Esophageal Cancer?

18:15-18:20 – Intruduction

18:20-18:40 – Immunotherapy Potential in Esophageal Cancer
Alexey Tryakin, RU

18:40-19:10 – New Immune Combinations for Gastric and Esophageal-Gastric Junction Cancer
Mikhail Fedyanin, RU

19:10-19:35 – Panel Discussion

Hall 2
18:15-19:25 – Satellite Symposium AstraZeneca

AstraZeneca medical satellite symposia

New opportunities in personalized therapy of breast cancer?

Chairmen:
Ludmila Zhukova, RU
Elena Artamonova, RU

18:15-18:20 – Welcome remarks

18:20-18:45 – New hope for high risk patients with early BRCA-associated breast cancer
Ludmila Zhukova, RU

18:45-19:10 – Is a breakthrough possible in the therapy of pretreated patients with metastatic HER2-positive breast cancer?
Elena Artamonova, RU

19:10-19:20 – Q&A session

19:20-19:25 – Closing remarks


Note: Each 20-minute slot for clinical case discussion includes 15’ case presentation and 5’ Q&A/panel discussion.


Friday, June 11th 2021 (Central European Summer Time)

SESSION 3. Sarcoma and GIST

Chairs:
Alexander Fedenko, RU
Silvia Stacchiotti, IT

09:00-09:25 – Practice changing studies in sarcoma and GIST
Silvia Stacchiotti, IT
09:25-09:30 – Q&A

09:30-09:50 – Diagnostic pathology in soft tissue sarcoma. What clinicians have to know?
Paolo Dei Tos, IT
09:50-09:55 – Q&A

09:55-10:20 – Chemotherapy of localized and advanced soft tissue sarcoma. Is there a room for personalized treatment?
Robin Jones, UK
10:20-10:25 – Q&A

10:25-10:50 – Pediatric sarcoma in adults
Jean-Yves Blay, FR
10:50-10:55 – Q&A

10:55-11:20 – Treatment options of retroperitoneal sarcoma after the STRASS study results
Silvie Bonvalot, FR
11:20-11:25 – Q&A

11:25-12:25 – Clinical case discussion (3x20’)
Andrey Kulaga, RU
Anastasia Tararykova, RU
Vitalij Egorenkov, RU


12:35-13:35 – Virtual Lunch Break

Hall 1
12:35-13:35 – Satellite Symposium Roche

Satellite Symposium Roche

Stages of implementation of Personalized Medicine.
The role of Complex Genomic Profiling (CGP)

Chairman:
Anton Snegovoy, RU

12:35-12:55 – Search for new opportunities for the development of Personal Healthcare in Russia. Role of the data and evidence in real clinical practice
Ali Mudunov, RU

12:55-13:15 – Value of molecular genetic diagnostic methods in patients with tumors of undetected primary localization. Clinical decision support system (Peer-To-Peer, Molecular Tumor Board)
Anton Snegovoy, RU

13:15-13:35 – Experience of Complex Genomic Profiling application in clinical practice. Molecular target therapy of the head and neck tumors
Maxim Pak, RU

Hall 2
12:35-13:35 – Satellite Symposium Pfizer

Pfizer Satellite symposium

RCC: from first line clinical trials data to real world application

Chairman:
Vsevolod Matveev, RU

12:35-12:40 – Introduction
Vsevolod Matveev, RU

12:40-12:50 – RCC first line therapy: clinical guidelines discussion
Vsevolod Matveev, RU

12:50-13:10 – The role of IO-TKI combinations in first line therapy
Alexey Kalpinsky, RU

13:10-13:30 – AE management while treating with IO-TKI therapy
Maria Volkova, RU

13:30-13:35 – Q&A


SESSION 4. Breast carcinoma

Chairs:
Giuseppe Curigliano, IT
Timur Mitin, USA
Mona Frolova, RU

13:50-14:15 – Practice changing studies in early stages
Nadia Harbeck, DE
14:15-14:20 – Q&A

14:20-14:45 – Practice changing studies in metastatic disease
Giuseppe Curigliano, IT
14:45-14:50 – Q&A

Treatment intensification and de-escalation in nonmetastatic disease. Whom and when?

14:50-15:10 – Surgeon`s perspectives
Alexander Petrovsky, RU

15:10-15:30 – Radiotherapist`s perspectives
Timur Mitin, USA

15:30-15:50 – Medical oncologist’ perspectives
Mona Frolova, RU

15:50-16:10 – Q&A, panel discussion

16:10-17:10 – Clinical case discussion (3x20’)
Elena Glazkova, RU
Elena Tsareva, RU
Olga Gorbacheva, RU


17:10-17:20 – Adjourn and Closing Remarks


Note: Each 20-minute slot for clinical case discussion includes 15’ case presentation and 5’ Q&A/panel discussion.